rituximab

Janssen gets expanded EC nod for blood cancer combo drug Imbruvica plus rituximab
Pharmaceutical Business Review
Tue, 09/8/20 - 10:41 am
JNJ
Janssen
Europe
Imbruvica
rituximab
CLL
Amgen/Allergan’s rituximab biosimilar could be $4bn blockbuster
Pharmaforum
Wed, 03/11/20 - 10:45 am
Amgen
Allergan
biosimilars
Roche
rituximab
AbbVie submits sNDA to FDA for IMBRUVICA, Rituximab combo for CLL
Pharmaceutical Business Review
Mon, 11/11/19 - 10:58 am
AbbVie
Imbruvica
rituximab
CLL
SLL
DEAL WATCH: Biosimilars, Biosimilars and More Biosimilars
Big Molecule Watch
Sun, 11/10/19 - 07:55 pm
biosimilars
Henlius
Ascentage
rituximab
Bioeq
Alvotech
Coherus
Biogen
Samsung Bioepis
FDA approves first biosimilar for NHL
BioCentury
Thu, 11/29/18 - 12:00 am
Celltrion
Teva Pharmaceutical
non-Hodgkin's lymphoma
Truxima
biosimilars
rituximab
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Sat, 11/3/18 - 12:39 pm
Novartis
Sandoz
rituximab
biosimilars
Roche
GSK trials Benlysta/rituximab combo for lupus
Pharma Times
Thu, 03/22/18 - 10:31 pm
GSK
clinical trials
Benlysta
rituximab
lupus
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Yahoo
Fri, 11/4/16 - 09:18 am
FDA
Genentech
Halozyme
rituximab
blood cancer
Roche's Gazyva notches early trial success
BioPharma Dive
Fri, 05/27/16 - 12:51 pm
Roche
Gazyva
clinical trials
rituximab
follicular lymphoma
AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA
Yahoo
Fri, 11/13/15 - 10:59 am
AbbVie
Imbruvica
bendamustine
rituximab
chronic lymphocytic leukemia
FDA
Teva announces additional regulatory exclusivity for TREANDA
The Fly on the Wall
Wed, 11/27/13 - 08:41 am
Teva
Treanda
rituximab
indolent non-Hodgkin's lymphoma
Boxed Warning of HBV Risk Added to Rituxan, Arezerra
Med Page Today
Thu, 09/26/13 - 10:28 am
warnings
Rituxan
hepatitis B
Arezerra
ofatamumab
rituximab
Celgene's candidates for non-Hodgkin's lymphomas show positive results
The Fly on the Wall
Thu, 06/20/13 - 12:19 pm
Celgene
non-Hodgkin's lymphoma
Revlimid
rituximab
Emergent Biosolutions to expand clinical trial of TRU-016 and rituximab
Reuters
Fri, 04/5/13 - 11:06 am
Emergent BioSolutions
rituximab
TRU-016
CLL
Results from a Randomized Study of REVLIMID® (Lenalidomide) and Rituximab (R2) in Patients with Recurrent Follicular Lymphoma Presented at ASCO
Yahoo/Business Wire
Sun, 06/3/12 - 11:10 am
Revlimid
rituximab
follicular lymphoma
Cellgene
Phase II Data Evaluating Clinical Benefit of Revlimid Plus Rituximab for Patients with Untreated Indolent B-Cell Lymphomas Presented at International Conference on Malignant Lymphoma
Yahoo/BusinessWire
Sat, 06/18/11 - 10:00 am
Revlimid
lymphoma
rituximab
Novartis plans trial of equivalent to Roche drug
Marketwatch
Mon, 01/10/11 - 12:16 pm
Roche
Novartis
biosimilars
Rituxan
Sandoz
rheumatoid arthritis
rituximab